A 48-year-old female with a body mass index of 38 kg/m2 and previous insertion of an Orbera intragastric balloon (Bioenterics Intragastric Balloon, Apollo Endosurgery, Austin, TX) 7 days before presented with vomiting, tachycardia, and hypotension with tenderness in the upper abdomen. Blood analyses showed elevated C-reactive protein, renal failure, and electrolyte disorder. Abdominal computed tomography (CT) showed gastric occlusion due to the placement in the pylorus, with signs of gastric necrosis and extensive portal pneumatosis (Figure 1). No signs of perforation were seen. Fluid resuscitation was provided along with proton pump inhibitors (PPIs), antibiotics, and nil per os restriction. Gastroscopy showed gastric wall necrosis, so removal of the balloon was performed endoscopically. The patient was discharged 3 days later, with normal blood tests. A month later, abdominal CT showed no portal pneumatosis.
Figure 1. Abdominal computed tomography showing (A) extensive portal pneumatosis among all the liver segments (arrow) and (B) the intragastric balloon with radiolucent zone (asterisk) causing occlusion at the pyloric level and gastric wall pneumatosis.
The main cause of occlusion after intragastric balloon placement is the spontaneous deflation and migration of the balloon. Gastric occlusion is rare; one study of 2,515 patients showed 19 presenting with gastric occlusion (0.76%).1 Although the major complications are expected 3 months after intervention, gastric occlusion seems to be more frequent within the first days.2 This complication is a diagnostic challenge because 7.4% of the patients presented with non-pathological vomiting during the first week post insertion.3 In case of high inflammatory markers or hemodynamic instability, the performance of CT is mandatory. Portal venous gas is a consequence of the compression of the gastric wall and subsequent ischemia. In case of iatrogenic origin, this sign is resolved spontaneously when the cause is treated.4 Prognosis depends on whether the balloon is removed to stop the progression to perforation. The appropriate equipment to undertake this technique is an endoscopic 25-gauge needle and a syringe to puncture and suction liquid for deflation. Surgical removal is not recommended, and it is only strictly indicated when there is evidence of perforation.5,6 This complication can be easily misdiagnosed, and its evolution depends on an early onset of the treatment.
Author contributions: All authors contributed equally to manuscript creation. X. Quer Vall is the article guarantor.
Financial disclosure: None to report.
Informed consent was obtained for this case report.
Correspondence: Maria Saladich-Cubero, University Hospital of Vic, C. Francesc Plà el Vigatà s/n 08500, Vic, Barcelona, Spain (email@example.com).
Received June 19, 2016; Accepted July 27, 2016
- Genco A, Bruni T, Doldi S, et al. BioEnterics intragastric balloon: The Italian experience with 2,515 patients. Obes Surg. 2005;15:1161–4. Article | PubMed
- Genco A, Maselli R, Frangella F, et al. Intragastric balloon for obesity treatment: Results of a multicentric evaluation for balloons left in place for more than 6 months. Surg Endosc. 2015;29(8):2339–43. Article | PubMed
- Khalaf NI, Rawat A, Buehler G. Intragastric balloon in the emergency department: An unusual cause of gastric outlet obstruction. J Emerg Med. 2014;46(4):e113–6. Article | PubMed
- Nelson AL, Millington TM, Sahani D, et al. Hepatic portal venous gas: The ABCs of management. Arch Surg. 2009;144(6):575–81. Article | PubMed
- Rodríguez-Hermosa JI, Roig-García J, Gironès-Vilà J, et al. Gastric necrosis: A possible complication of the use of the intragastric balloon in a patient previously submitted to Nissen fundoplication. Obes Surg. 2009;19(10):1456–9. Article | PubMed
- Koutelidakis I, Dragoumis D, Papaziogas B, et al. Gastric perforation and death after the insertion of an intragastric balloon. Obes Surg. 2009;19(3):393–6. Article | PubMed
© 2016 Saladich-Cubero et al. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0.